Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 11, 2026, 4:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 1,947 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: COVID-19 Pneumonia Clear all
Terminated Phase 2 Interventional Results available

A Study to Evaluate the Effect of RBT-9 on Progression of COVID-19 in High-Risk Individuals (The PREVENT Study)

NCT04364763
View directory record Official record
Conditions
COVID-19
Interventions
RBT-9 (90 mg), 0.9% sodium chloride (normal saline)
Drug
Lead sponsor
Renibus Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
5
States / cities
New Smyrna Beach, Florida • Berkley, Michigan • El Paso, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2023 · Synced Oct 11, 2026, 4:35 AM EDT
Terminated Phase 2 Interventional Results available

Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection

NCT04381052
View directory record Official record
Conditions
COVID-19
Interventions
Clazakizumab, Placebo
Drug · Other
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 8, 2022 · Synced Oct 11, 2026, 4:35 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Neural and Cognitive Consequences of COVID-19 Survival

NCT06208943
View directory record Official record
Conditions
COVID Long-Haul, COVID-19, COVID-19 Pandemic, Brain Fog, Memory Deficits, Concentration Ability Impaired, Fatigue
Interventions
cross-sectional MRI and EEG assessments (NO INTERVENTION)
Other
Lead sponsor
San Francisco Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 70 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 12, 2024 · Synced Oct 11, 2026, 4:35 AM EDT
Suspended No phase listed Observational Accepts healthy volunteers

Patients' Attitudes Toward and Experiences With Buprenorphine Treatment

NCT05121428
View directory record Official record
Conditions
Opioid-use Disorder, Acceptability of Health Care, Opioid-Related Disorders
Interventions
Not listed
Lead sponsor
Cambridge Health Alliance
Other
Eligibility
18 Years and older
Enrollment
817 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 11, 2025 · Synced Oct 11, 2026, 4:35 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Cannabidiol in Patients With COVID-19 and Cardiovascular Disease or Risk Factors

NCT04615949
View directory record Official record
Conditions
COVID-19, Cardiovascular Diseases, Cardiovascular Risk Factor
Interventions
Cannabidiol, pharmaceutically produced with < 5 ppm THC, Placebo
Drug
Lead sponsor
Cardiol Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
7
States / cities
Phoenix, Arizona • Cutler Bay, Florida • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 11, 2026, 4:35 AM EDT
Recruiting No phase listed Observational

The Effect of COVID-19 Pandemic on Adolescent and Young Adult Cancer Patients and Survivors

NCT04551378
View directory record Official record
Conditions
COVID-19 Infection, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions
Quality-of-Life Assessment, Survey Administration
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 39 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 11, 2026, 4:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Dose Exploration Intramuscular/Intravenous Prophylaxis Pharmacokinetic Exposure Response Study

NCT05872958
View directory record Official record
Conditions
COVID-19
Interventions
AZD3152, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
4
States / cities
Anniston, Alabama • Cullman, Alabama • Scottsdale, Arizona + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2025 · Synced Oct 11, 2026, 4:35 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Point of Care Evaluation of Novir 2019-nCoV Immunoglobulin G/ Immunoglobulin M (IgG/IgM) Antibody Test (Collodial Gold)

NCT04902911
View directory record Official record
Conditions
Covid19
Interventions
COVID-19 SARS-CoV IgG/IgM antibody rapid test
Device
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
21 Years and older
Enrollment
91 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Wauwatosa, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 8, 2024 · Synced Oct 11, 2026, 4:35 AM EDT
Completed Not applicable Interventional

Clinical Evaluation of the Panbio™ COVID-19/Flu A&B Rapid Panel Professional Use Product Using Mid-Turbinate Nasal Swabs

NCT05630365
View directory record Official record
Conditions
COVID-19, Influenza A, Influenza Type B
Interventions
Panbio™
Diagnostic Test
Lead sponsor
Abbott Rapid Dx
Industry
Eligibility
Not listed
Enrollment
1,129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 9, 2023 · Synced Oct 11, 2026, 4:35 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

A Study to Learn About COVID-19 RNA-Based Variant-Adapted Vaccine Candidate(s) Against SARS-CoV-2 in Participants Ages 12 Through 64 Years Considered at Higher Risk of Severe COVID-19, and Participants Ages ≥65 Years

NCT07069309
View directory record Official record
Conditions
COVID-19, SARS-COV-2 Infection
Interventions
BNT162b2 (2025/2026 recommended SARS-CoV-2 strain)
Biological
Lead sponsor
BioNTech SE
Industry
Eligibility
12 Years and older
Enrollment
774 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
19
States / cities
Walnut Creek, California • Milford, Connecticut • Washington D.C., District of Columbia + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 11, 2026, 4:35 AM EDT
Terminated Phase 1 Interventional Results available

Pharmacokinetics of Sotrovimab as Pre-exposure Prophylaxis for COVID-19 in Hematopoietic Stem Cell Transplant Recipients, COVIDMAB Study

NCT05135650
View directory record Official record
Conditions
COVID-19 Infection, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions
Questionnaire Administration, Sotrovimab, Biospecimen Collection
Other · Biological · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 13, 2025 · Synced Oct 11, 2026, 4:35 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Cyclosporine For The Treatment Of COVID-19(+)

NCT04492891
View directory record Official record
Conditions
SARS (Disease)
Interventions
Cyclosporine, Standard of Care Treatment
Drug · Other
Lead sponsor
Bryan Burt, MD
Other
Eligibility
18 Years to 90 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 20, 2023 · Synced Oct 11, 2026, 4:35 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluating a Community-Led COVID-19 Testing Intervention to Address Mistrust - Study 1

NCT06650462
View directory record Official record
Conditions
COVID-19, Trust
Interventions
Community-led discussion
Behavioral
Lead sponsor
Old Dominion University
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 11, 2026, 4:35 AM EDT
Withdrawn Phase 2 Interventional

Dose-Ranging Study to Assess the Safety and Efficacy of Melatonin in Outpatients Infected With COVID-19

NCT04784754
View directory record Official record
Conditions
COVID-19
Interventions
Melatonin, Placebo
Drug
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jul 22, 2022 · Synced Oct 11, 2026, 4:35 AM EDT
Completed Phase 2 Interventional Results available

Evaluating Safety, Pharmacokinetics and Clinical Benefit of Silmitasertib (CX-4945) in Subjects With Moderate COVID-19

NCT04663737
View directory record Official record
Conditions
Covid19
Interventions
Silmitasertib, SOC
Drug
Lead sponsor
Senhwa Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Gainesville, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 16, 2025 · Synced Oct 11, 2026, 4:35 AM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate the Safety, Tolerability, and Efficacy of BGE-175 in Hospitalized Adults With Coronavirus Disease 2019 (COVID-19) That Are Not in Respiratory Failure

NCT04705597
View directory record Official record
Conditions
Covid19
Interventions
BGE-175, Placebo
Drug · Other
Lead sponsor
BioAge Labs, Inc.
Industry
Eligibility
50 Years and older
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
11
States / cities
Mesa, Arizona • Chula Vista, California • Long Beach, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2023 · Synced Oct 11, 2026, 4:35 AM EDT
Completed Not applicable Interventional

Proning Early in Awake COVID-19 Hypoxic Respiratory Failure (PREACHR) Study

NCT05130541
View directory record Official record
Conditions
Covid19, Respiratory Failure
Interventions
Proning, Supportive Care
Behavioral · Other
Lead sponsor
New York Hospital Queens
Other
Eligibility
18 Years and older
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Flushing, New York
Source: ClinicalTrials.gov public record
Updated Nov 23, 2021 · Synced Oct 11, 2026, 4:35 AM EDT
Completed Phase 1Phase 2 Interventional

JINZHEN for Treatment of Mild to Moderate COVID-19

NCT05092503
View directory record Official record
Conditions
COVID-19
Interventions
JINZHEN Granules for Oral Solution, Placebo
Drug
Lead sponsor
Lianyungang Kanion Group, Ltd.
Industry
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
10
States / cities
Canyon Country, California • Hialeah Gardens, Florida • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2024 · Synced Oct 11, 2026, 4:35 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Detection of Integrin avb6 in IPF, PSC, and COVID19 Using PET/CT

NCT03183570
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis, Primary Sclerosing Cholangitis, Covid19 Pneumonia
Interventions
[18F]FP-R01-MG-F2
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2025
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Oct 11, 2026, 4:35 AM EDT
Completed Phase 2 Interventional Results available

SPI-1005 Treatment in Severe COVID-19 Patients

NCT04483973
View directory record Official record
Conditions
Covid19, Coronavirus, Coronavirus Infection, Corona Virus Infection
Interventions
Ebselen, Placebo
Drug
Lead sponsor
Sound Pharmaceuticals, Incorporated
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
7
States / cities
New Haven, Connecticut • Boise, Idaho • Kansas City, Kansas + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 11, 2026, 4:35 AM EDT
Completed No phase listed Observational

Assessment of Analgesics and Sedatives in Mechanically Ventilated Patients With COVID-19

NCT05336656
View directory record Official record
Conditions
COVID-19, ARDS, Withdrawal Syndrome, Iatrogenic Disease
Interventions
Not listed
Lead sponsor
Wilkes University
Other
Eligibility
18 Years to 90 Years
Enrollment
353 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Wilkes-Barre, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 26, 2023 · Synced Oct 11, 2026, 4:35 AM EDT
Completed Phase 4 Interventional

FREEDOM COVID-19 Anticoagulation Strategy

NCT04512079
View directory record Official record
Conditions
COVID-19, SARS-CoV-2
Interventions
Enoxaparin, Apixaban
Drug
Lead sponsor
Valentin Fuster
Other
Eligibility
18 Years and older
Enrollment
3,460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 16, 2023 · Synced Oct 11, 2026, 4:35 AM EDT